Skip to main content

Physician Search

 


Displaying 1 - 1 of 1

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Lymphoma

This is the study of the PI3K inhibitor Zandelisib (ME-401) in subjects with relapsed / refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy
Lymphoma
II
Dholaria, Bhagirathbhai
NCT03768505
VICCPCL1913